HLA Panel Reactive IgG Antibodies PRA Class II Quantitative Test
Comprehensive Introduction to HLA Antibody Testing
The HLA Panel Reactive IgG Antibodies PRA Class II Quantitative Test represents a critical advancement in transplant medicine, providing essential data for successful organ transplantation outcomes. This sophisticated diagnostic assessment measures the presence and concentration of IgG antibodies specifically targeting Human Leukocyte Antigen (HLA) Class II molecules, which play a fundamental role in immune system recognition and response to foreign tissues.
Class II HLA antigens are primarily expressed on antigen-presenting cells and are crucial for initiating immune responses against transplanted organs. The quantitative measurement of these antibodies helps transplant teams evaluate the immunological risk profile of potential recipients, enabling more precise matching between donors and recipients to minimize rejection episodes and improve long-term graft survival.
What This Test Measures and Detects
The HLA Panel Reactive IgG Antibodies PRA Class II Quantitative Test specifically identifies and quantifies:
- IgG antibodies against HLA-DR, HLA-DQ, and HLA-DP antigens
- Panel Reactive Antibody (PRA) percentage for Class II HLA molecules
- Specific antibody strength and concentration using Mean Fluorescence Intensity (MFI)
- Crossmatch compatibility predictions for potential donors
- Historical sensitization events from previous transplants, pregnancies, or transfusions
Using state-of-the-art Luminex X-Map technology, this test provides highly sensitive and specific detection of HLA Class II antibodies with exceptional precision. The quantitative nature of the results allows for better risk stratification and more informed clinical decision-making throughout the transplant process.
Who Should Consider This Test
Primary Candidates Include:
- Patients awaiting kidney, liver, heart, lung, or pancreas transplantation
- Individuals with previous organ transplant history
- Patients with multiple blood transfusions in their medical history
- Women with previous pregnancies, particularly those with multiple children
- Patients experiencing unexplained graft dysfunction or rejection episodes
- Individuals being evaluated for bone marrow or stem cell transplantation
Clinical Indications and Symptoms:
- Pre-transplant evaluation and waitlist management
- Post-transplant monitoring for antibody-mediated rejection
- Unexplained graft dysfunction or deterioration
- History of sensitizing events requiring immunological assessment
- Evaluation for desensitization protocols
Significant Benefits of HLA Class II Antibody Testing
Undergoing the HLA Panel Reactive IgG Antibodies PRA Class II Quantitative Test provides numerous clinical advantages:
Enhanced Transplant Success
By identifying pre-existing HLA Class II antibodies, transplant teams can avoid incompatible donor-recipient matches, significantly reducing the risk of hyperacute and acute antibody-mediated rejection. This proactive approach leads to better graft function and longer transplant survival rates.
Personalized Treatment Planning
The quantitative results enable physicians to tailor immunosuppression regimens based on individual antibody profiles. Patients with high PRA percentages may benefit from more intensive induction therapy or desensitization protocols before transplantation.
Improved Organ Allocation
Accurate PRA calculations help transplant centers prioritize patients on waiting lists based on their immunological risk profiles, ensuring that organs are allocated to patients with the best chance of successful outcomes.
Early Detection of Sensitization
Regular monitoring allows for early detection of new antibody development, enabling timely intervention before clinical rejection becomes apparent. This proactive monitoring is particularly important for patients with previous sensitizing events.
Understanding Your Test Results
Interpreting PRA Percentages
The Panel Reactive Antibody (PRA) percentage indicates the proportion of the general population against which a patient has detectable HLA antibodies:
- 0-10% PRA: Low sensitization – broad donor compatibility
- 11-79% PRA: Moderate sensitization – some donor limitations
- 80-100% PRA: Highly sensitized – significant donor challenges
Quantitative Antibody Strength
Mean Fluorescence Intensity (MFI) values provide information about antibody strength:
- Low MFI (<1000): Weak antibodies, may not be clinically significant
- Moderate MFI (1000-5000): Potentially relevant antibodies
- High MFI (>5000): Strong antibodies with clinical significance
Clinical Correlation
It’s essential to interpret results in the context of your complete clinical picture. Your transplant team will consider:
- Specific antibody specificities and their prevalence in the donor population
- Historical antibody patterns and trends over time
- Current clinical status and transplant urgency
- Available desensitization options and their success rates
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| HLA Panel Reactive IgG Antibodies PRA Class II Quantitative Test | $376 USD | $550 USD |
Test Specifications
- Turnaround Time: 10-12 days
- Sample Type: 3 mL (1.5 mL minimum) serum from 1 SST
- Shipping Requirements: Refrigerated or frozen
- Special Instructions: Collect specimen preferably 48 hours after dialysis. Provide brief clinical history.
- Technology: Luminex X-Map methodology
Nationwide Accessibility
GGC DNA maintains comprehensive testing facilities across the United States, ensuring convenient access to this essential transplant evaluation tool. Our network includes specialized collection centers in major metropolitan areas including:
- New York City and surrounding tri-state area
- Los Angeles and Southern California region
- Chicago and Illinois metropolitan area
- Houston and Texas Gulf Coast locations
- Phoenix and Arizona valley facilities
- And numerous additional locations nationwide
Our experienced phlebotomy teams are trained in proper sample collection techniques specific to transplant immunology testing, ensuring sample integrity and accurate results.
Take the Next Step Toward Transplant Success
Don’t let uncertainty about your immunological status delay your transplant journey. The HLA Panel Reactive IgG Antibodies PRA Class II Quantitative Test provides the critical information needed to optimize your transplant outcomes and minimize rejection risks.
Schedule your test today by calling our dedicated transplant testing line at +1(267) 388-9828 or book your appointment online through our secure patient portal. Our transplant immunology specialists are available to answer your questions and guide you through the testing process.
Early detection and proper management of HLA antibodies can significantly impact your transplant success and long-term health. Trust GGC DNA for accurate, reliable HLA antibody testing that transplant teams nationwide depend on for critical clinical decisions.
